Pro-Lifers Demand Answers From Trump Admin After ‘Shocking’ Abortion Pill Approval

Pro-life advocates are demanding answers from the White House after the FDA approved a new abortion pill in a “shocking” decision earlier this week.

The FDA on Tuesday gave approval for Evita Solutions to distribute mifepristone, a drug that is used to end the life of an unborn child in up to 63% of all abortions. After a pregnant woman takes mifepristone, her unborn child is cut off from the nutrients it needs to survive and is effectively starved to death. A different drug is then taken to induce labor and expel the deceased baby from the mother. 

The fatal drug has been increasingly available after the Biden administration allowed it to be mailed by doctors. Leftist activists ship the drugs illegally across the country with impunity. 

Senator Josh Hawley (R-MO) called the approval “shocking” and said he had lost faith in FDA leadership. 

“This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,” Hawley wrote on X. 

“FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA,” he added. 

Rep. Mark Harris (R-NC) also questioned the move.

“Wow! The FDA just approved a generic version of the abortion pill, Mifepristone, a drug that ends a baby’s life 100% of the time and harms mothers. The FDA announced a new safety study just days ago, so why this new move now?” he wrote on X.

Only two other drug companies, Danco Labs and Genbiopro, were previously approved to distribute the life-ending drug. The FDA wrote to Evita Solutions on September 30 that it had “concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval.”

Evita Solutions says on its website that “medical abortion care is rife with medically unnecessary restrictions and social stigma in the United States” and that it “believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.”

In response to questions about the drug’s approval, Health and Human Services Communications Director Andrew Nixon told The Daily Wire that the FDA “has very limited discretion in deciding whether to approve a generic drug. By law, the Secretary of Health and Human Services must approve an application if it demonstrates that the generic drug is identical to the brand-name drug.”

Nixon added that applicants for generic drugs do not need to submit independent evidence proving safety and efficacy. 

“HHS is conducting a study of the reported adverse effects of mifepristone to ensure the FDA’s risk mitigation program for the drug is sufficient to protect women from unstated risks,” Nixon added. “The FDA does not endorse any drug product and directs prescribers to follow all labeling.”

The decision is already drawing backlash from pro-life advocates who have long warned about the dangers of the drug. Kelsey Pritchard, the director of state affairs for SBA Pro-Life America, called the decision “reckless.”

“This does nothing to help and fix the problem that we have with abortion drugs and mail-order abortion drugs, and instead puts a cheap drug on the market so that more unborn lives are taken and more women and girls end up in the ER,” she told The Daily Wire. 

Pritchard said that the Trump administration should reinstate restrictions on the mailing of mifepristone that the Biden administration loosened. 

“This decision is not MAGA. It is not MAHA, adding a new life ending drug to the market doesn’t make America greater or healthier, and this is not something that we would expect, especially at this time,” she added, calling for pro-life Republicans to call out the decision. 

Last month, HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary told Republican attorneys general that they were studying the safety of mifepristone. Some studies have shown that the drug is not only fatal to the unborn child but can also bring serious health risks to the mother.